# Product Transference Study of Testagen™ TDS®-Testosterone

> **NCT02733133** · PHASE2 · UNKNOWN · sponsor: **Transdermal Delivery Solutions Corp** · enrollment: 96 (estimated)

## Conditions studied

- Hypogonadotropism

## Interventions

- **DRUG:** Testagen® TDS Testosterone 5% HypoSpray®

## Key facts

- **NCT ID:** NCT02733133
- **Lead sponsor:** Transdermal Delivery Solutions Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2025-10
- **Final completion:** 2025-12
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2024-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733133, "Product Transference Study of Testagen™ TDS®-Testosterone". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02733133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*